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Abstract
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is regarded as effective surgical treatments in
patients with peritoneal metastasis. This study aimed to evaluate the clinical outcomes of CRS and HIPEC in patients with
appendiceal or colorectal cancer with peritoneal carcinomatosis.
A total of 66 patients who underwent CRS with HIPEC for appendiceal or colorectal cancer with peritoneal metastasis at 2 tertiary
referral centers in Korea were evaluated between July 2014 and March 2016. The perioperative outcomes and postoperative
complications were evaluated prospectively.
The mean peritoneal cancer index (PCI) was 15.3±10.5. The distributions thereof were as follows: PCI<10, 33.3%; PCI 10–19,
36.4%; and PCI≥20, 30.3%. Regarding completeness of cytoreduction (CC), 59.1% of patients achieved CC-0, with 18.2% showing
CC-1 and 22.7% showing CC-2. Themean operation time was 9.4hours, and the mean hospital stay was 20.2 days. The overall rate
of short-term complications was 74.2%; the rate of long-term complications was 10.6%. In the short-term period, most
complications were grades I-II complications (62.1%), compared to grades III-V (12.1%). All long-term complications, occurring in
10.6% of patients, were grades III-V.
In this study, CRS with HIPEC was deemed feasible and safe for treating stage IV appendiceal or colorectal cancer with peritoneal
carcinomatosis in Koreans.
Abbreviations: ASA = American Society of Anesthesiologists, BMI = body mass index, CC = completeness of cytoreduction,
CRS = cytoreductive surgery, CT = computed tomography, ECOG = Eastern Cooperative Oncologic Group, HIPEC = hyperthermic
intraperitoneal chemotherapy, ICU= intensive care unit, PCI= peritoneal cancer index, PSDSS= Peritoneal Surface Disease Severity
Score.
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peritoneal neoplasms[1,2]1. Introduction
Peritoneal carcinomatosis is the second most common metastatic
lesion in patients with stage IV colorectal cancer, with a cancerEditor: Adrian Murillo.
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1recurrence incidence of 10% to 35%. When free intraperito-
neal cancer cells are exfoliated from a primary cancer, they can be
disseminated and lead to peritoneal metastasis or local recur-
rence.[3] Meanwhile, cytoreductive surgery (CRS) with hyper-
thermic intraperitoneal chemotherapy (HIPEC) is based on the
concept that microscopic residual tumors can be eradicated by
direct penetration of anticancer drugs into tumor cells at 42°C to
43°C after removal of the macroscopic tumor.[4] According to the
randomized controlled trial by Verwaal et al,[5,6] the median
survival after CRS with HIPEC in patients with peritoneal
metastasis of colorectal origin was improved above that achieved
with standard systemic chemotherapy (22.3 vs 12.6 months,
P= .032).[5,6] In a phase II multicentric French study, Elias et al[7]
reported that patients who underwent surgery with perioperative
intraperitoneal chemotherapy experienced a median survival of
30.1 months with 27% of 5-year overall survival rates.
Although CRS with HIPEC offers advantages in treating
peritoneal metastasis, the procedure is technically demanding and
must be performed by a highly experienced surgical team.
Moreover, a high rate of postoperative complications and a steep
learning curve hinder wider performance of CRS with
HIPEC.[8–12] Since July 2014, our institutions began offering
CRS with HIPEC for patients with colorectal cancer with
Park et al. Medicine (2017) 96:21 Medicineperitoneal carcinomatosis. In this study, we aimed to evaluate
clinical outcomes of CRS with HIPEC and its feasibility in
treating Korean patients with appendiceal or colorectal cancer
with peritoneal carcinomatosis.2. Methods
2.1. Study population and data collection
A colorectal surgeon (SH Baik) started CRC with HIPEC at
Severance Hospital in July 2014, and since then, a total of 66
patients with peritoneal metastasis originating from colorectal or
appendiceal cancer have underwent CRS with HIPEC at 2
tertiary referral hospitals (Severance Hospital and Gangnam
Severance Hospital) of the Yonsei University Health System as of
March 2016. Patients were diagnosed with peritoneal metastases
preoperatively via abdomino-pelvic computed tomography (CT),
positron emission tomography-CT, or diagnostic laparoscopy.
Among patients diagnosed with peritoneal carcinomatosis,
patients younger than 80 years with an Eastern Cooperative
Oncologic Group (ECOG) score less than 2 were included in this
study. Patients who exhibited massive involvement of metastatic
lesions, which are unresectable or agglomerated in the small
bowel or its mesentery, on preoperative imaging studies or
intraoperative ﬁndings were contraindicated for HIPEC. Patients
who underwent emergent operations or only early postoperative
intraperitoneal chemotherapy without HIPEC were excluded.
Before surgery, eligibility for CRSwithHIPECwas discussed in
a multidisciplinary colorectal team conference using preoperative
radiologic examinations. Clinical outcomes and postoperative
complications were collected prospectively in an electronic
database (Yonsei Colorectal Database). This study was approved
by the Institutional Review Board of our institution (IRB No. 3-
2016-0196).2.2. Evaluation parameters
Preoperatively, patients were evaluated for combined morbidities
and the American Society of Anesthesiologists (ASA) classiﬁca-
tion, along with assessment of previous chemotherapy history or
abdominal surgery. Peritoneal Surface Disease Severity Score
(PSDSS) was determined from stages I to IV, which were assessed
according to 3 categories based on clinical symptoms, extent of
carcinomatosis (peritoneal cancer index [PCI] on preoperative
CT scan or ﬁrst exploration), and histopathology of the primary
tumor.[13,14]
PCI was assessed through the 13 abdomino-pelvic regions.
Each region was graded using the following scale: 0 points,
absence of tumor; 1 point, tumor less than 0.5cm; 2 points,
tumor from 0.5cm to 5cm; and 3 points, tumor larger than 5cm.
Completeness of cytoreduction (CC) was assessed according to
the extent of the remnant tumor: CC-0, complete removal of
visible tumor; CC-1, remnant tumor less than 0.25cm; CC-2,
residual tumor between 0.25cm and 2.5cm; and CC-3, visible
tumor larger than 2.5cm in diameter.
Synchronous operations were performed with resection of the
primary tumor followed by a peritonectomy. The length of stay in
the intensive care unit (ICU) was assessed from the day of the
operation to admittance in the general ward. The length of
hospital stay was calculated from the date of admission to
discharge. Patients received adjuvant chemotherapy based on the
regimens of FOLFOX, FOLFIRI, or capecitabine with targeted
cancer therapeutics, such as bevacizumab or cetuximab. The2interval of the ﬁrst postoperative chemotherapy was calculated as
the time elapsed from the date of the operation to the date the
patient received the ﬁrst cycle. Readmission was evaluated for
complication-related admission after discharge.
Postoperative complications were classiﬁed by the Clavien–-
Dindo classiﬁcation of surgical complications.[15,16] Short-term
complications were considered as those that developed within the
ﬁrst 30 postoperative days, while long-term complications were
evaluated when more than 30 days had elapsed.2.3. Surgical technique
Before CRS, bowel preparation was performed, except in patients
who had intestinal obstructions. Prophylactic antibiotics with a
third-generation cephalosporin were administered. CRS was
performed by resection of the metastatic organs from the primary
cancer with a peritonectomy. Parietal peritonectomy and visceral
resections were performed by following the Sugarbaker techni-
ques.[17,18] Anterior peritonectomy, upper quadrant peritonec-
tomy, pelvic peritonectomy, subphrenic peritonectomy, and
omental bursectomy were performed selectively, depending on
the site of peritoneal metastasis. HIPEC was performed by
circulating the mixed solution of 35mg/m2 of mitomycin-C and
3L of hypertonic solution (Dianeal, 1.5% Dextrose Peritoneal
Dialysis Solution). Mitomycin-C was inserted 17.5mg/m2
initially and 8.8mg/m2 at 30 and 60 minutes. The mixed
solution was circulated 800–1000mL/min in a HIPEC pump
(The Belmont Hyperthermic Pump) to maintain 42°C to 43°C for
90 minutes. The temperatures of both the inﬂow and outﬂow of
the HIPEC solution, as well as the patient’s body temperature,
were recorded every 5 minutes. Anastomosis of resected bowels
was performed after HIPEC. A diverting ostomy was performed
depending on the surgeon’s decision in consideration the risk of
anastomotic leakage or the extent of CRS. All patients were sent
to the ICU after surgery.3. Results
3.1. Patient characteristics
The mean age of the patients was 56.1 years old, with 51.5%
males and 48.5% females. Body mass index (BMI) of the patients
was 23.3±3.5 (range, 16.6–32.0). Overall, 40.9% of the patients
had co-morbidities, with 34.8% of the patients having an ASA
score of 3. The most frequent site of primary tumor was the
ascending colon. Before CRS with HIPEC, 24 patients (36.4%)
had a primary tumor with synchronous peritoneal metastasis,
whereas 42 patients (63.6%) had metachronous peritoneal
metastasis. In total, 50 patients had previously underwent
abdominal surgeries. Among them, 42 patients underwent
colorectal cancer surgery, and 3 patients had palliative surgery
before CRS plus HIPEC. All 3 cases of palliative surgery were
ileostomy formations to treat intestinal obstruction from
peritoneal carcinomatosis.
There were 63.6% of the patients who received systemic
chemotherapy before CRS with HIPEC (ﬁrst-line systemic
chemotherapy, 63.6%; second-line, 37.9%; third-line, 16.7%).
Synchronous organ metastases in addition to peritoneal
carcinomatosis were noted in 9 patients with liver metastasis
and 1 patient with lung metastasis. Regarding the histologic
differentiation of the primary colorectal cancer, moderate
differentiation was most common (62.1%). The mean value of
preoperative carcinoembryonic antigen was 30.8 ng/mL. In the
Table 1
Baseline characteristics of patients.
Variables N=66
Age, y 56.1±12.4 (24–76)
Sex
Male 34 (51.5)
Female 32 (48.5)
BMI, kg/m2 23.3±3.5 (16.6–32.0)
Combined morbidity 27 (40.9)
ASA
1 10 (15.2)
2 33 (50.0)
3 23 (34.8)
Primary cancer
Ascending colon cancer 18 (27.3)
Transverse colon cancer 5 (7.6)
Descending colon cancer 2 (3.0)
Sigmoid colon cancer 15 (22.7)
Rectosigmoid junction cancer 3 (4.5)
Rectal cancer 10 (15.2)
Cecal cancer 6 (9.1)
Appendiceal cancer 7 (10.6)
Presentation of peritoneal metastasis
Synchronous 24 (36.4)
Metachronous 42 (63.6)
History of previous abdominal surgery
Yes 50 (75.8)
No 16 (24.2)
Preoperative chemotherapy
1st line 42 (63.6)
2nd line 25 (37.9)
3rd line 11 (16.7)
Synchronous organ metastasis
Liver 9 (13.6)
Lung 1 (1.5)
Histology of primary colorectal cancer
Well-differentiated 3 (4.5)
Moderate-differentiated 41 (62.1)
Poor-differentiated 6 (9.1)
Mucinous 14 (21.2)
Unknown and missing 2 (3.0)
Preoperative hemoglobin 12.3±1.9 (7.0–16.8)
Preoperative albumin, g/dL 4.0±0.5 (2.4–5.0)
Preoperative CRP 23.4±40.2 (0.2–189.1)
Preoperative CEA, ng/mL 30.8±61.8 (0.5–338.0)
Peritoneal Surface Disease Severity Score (PSDSS)
Stage I 0 (0.0)
Stage II 38 (57.6)
Stage III 6 (9.1)
Stage IV 22 (33.3)
ASA=American Society of Anesthesiologists, BMI=body mass index, CEA= carcinoembryonic
antigen, CRP=C-reactive protein, PC=peritoneal carcinomatosis, PSDSS=Peritoneal Surface
Disease Severity Score.
Table 2
Intraoperative outcomes.
Variables N=66
Peritoneal Cancer Index, PCI
< 10 22 (33.3)
10–19 24 (36.4)
≥ 20 20 (30.3)
Mean±SD 15.3±10.5
Completeness of cytoreduction (CC) score
CC-0 39 (59.1)
CC-1 12 (18.2)
CC-2 15 (22.7)
Operative time, h 9.4±3.1 (3.4–19.6)
Estimated blood loss,
∗
mL 565 (215–1337)
∗
Intraoperative transfusion
Yes 18 (27.3)
No 48 (72.7)
Operative method
Open 65 (98.5)
Laparoscopic 1 (1.5)
Synchronous resection of primary tumor 24 (36.4)
Rt. hemicolectomy 12 (18.2)
Anterior resection 7 (10.6)
Low anterior resection 3 (4.5)
Total colectomy 2 (3.0)
Combined operations during CRS† 20 (30.3)
Cystectomy with ureteroneocystostomy 4 (6.1)
Segmental resection of ureter and ureterouerterostomy 2 (3.0)
Liver resection (segmentectomy, or wedge resection) 6 (9.1)
Intraoperative RFA 1 (1.5)
TAH & BSO 5 (7.6)
Splenectomy 1 (1.5)
Exicision of pancreatic mass 1 (1.5)
Stoma formation
None 43 (65.2)
Park et al. Medicine (2017) 96:21 www.md-journal.comassessment of PSDSS, 57.6% of the patients were stage II, which
was a higher rate than the 9.1%of stage III and 33.3%of stage IV
(Table 1).Colostomy 9 (13.6)
Ileostomy 12 (18.2)
Jejunostomy 2 (3.0)
CC= completeness of cytoreduction, RFA= radiofrequency ablation, TAH & BSO= total abdominal
hysterectomy & bilateral oophorectomy.
∗
Median (Interquartile range).
† Combined operations, except primary tumor resection and peritonectomy, were performed
additionally to remove metastatic sites of other organs.3.2. Intraoperative outcomes
In assessment of extent of peritoneal carcinomatosis, the mean
PCI was 15.3±10.5 (range, 1–39). 33.3% of the patients had a
PCI less than 10, 36.4% with a PCI of 10 to 19, and 30.3%
greater than PCI 20. CC-0 was accomplished in 59.1% of the
patients, and CC-1 was achieved in 18.2%. The mean operation
time was 9.4hours. Intraoperative transfusion was performed in327.3% of the patients, and the mean amount of intraoperative
blood loss was 565mL. HIPEC was performed by the open
method with the Coliseum technique, except in 1 case where the
laparoscopic approach was used. Synchronous resection of the
primary tumor during CRS plus HIPEC was performed in 24
patients (36.4%), whereas resection of the recurrent tumor was
performed in 42 patients (63.6%). Among all patients, 20
patients additionally underwent combined operations to remove
metastatic lesions of other organs during CRS. Total abdominal
hysterectomy with bilateral oophorectomy was performed in
7.6% of the patients. In addition, liver metastasis was treated by
surgical resection in 6 patients, and intraoperative radio-
frequency ablation in 1 patient. Two other patients with
synchronous liver metastasis were treated by systemic chemo-
therapy with targeted anticancer agents to induce resectable
conversion of metastatic liver lesions. Bladder invasion from
carcinomatosis was treated by cystectomy in 6.1% of the
patients. Stoma formation was performed in 34.8% of the
patients: colostomy (13.6%), ileostomy (18.2%), and jejunos-
tomy (3.0%) (Table 2).
Table 3
Postoperative clinical outcomes.
Variables N=66
Length of ICU stay, day 1.7±1.4 (0–7)
Length of hospital stay, day 20.2±13.5 (8–70)
Days to extubation, day 0.6±0.9 (0–6)
Days to 1st sips of water, day 4.7±3.3 (1–21)
Days to 1st soft diet, day 9.5±6.8 (3–44)
Days to removal of Levin tube, day 4.8±5.2 (0–29)
Days to removal of JP drain, day 13.4±8.0 (5–43)
Re-transferral to ICU after the operation
Sepsis 2 (3.0)
Postoperative bleeding 1 (1.5)
Postoperative chemotherapy
Yes 51 (77.3)
No 15 (22.7)
Regimen of 1st postoperative chemotherapy
Bevacizumab + FOLFIRI 20 (30.3)
Bevacizumab + FOLFOX 2 (3.0)
Cetuximab + FOLFIRI 17 (25.8)
Cetuximab + Irinotecan 1 (1.5)
Capcitabine 4 (6.1)
FOLFIRI 1 (1.5)
FOLFOX 6 (9.1)
Interval of 1st postoperative chemotherapy, week
Mean±SD 8.0±9.3 (2–55)
Median, IQR 5.0 (3–8)
Re-admission 6 (9.1)
ICU= intensive care unit, IQR= interquartile range, JP=Jackson–Pratt, SD= standard deviation.
Table 4
Postoperative complications according to the Clavien–Dindo
classiﬁcation.
Variables N=66
Short-term postoperative complications
(postoperative 30 days)
49 (74.2)
Grade I 18 (27.3)
Fever 7
Abdominal pain 2
Constipation 1
Nausea/vomiting 4
Voiding difﬁculty 2
Wound seroma 1
High output of jejunostomy 1
Grade II 23 (34.8)
Intestinal obstruction 3
Transfusion 5
Neutropenia 10
Thrombocytopenia 4
Tachycardia 1
Grade IIIa 3 (4.5)
Pleural effusion 1
Ureteral stricture 1
Postoperative bleeding 1
Grade IIIb 4 (6.1)
Anastomotic leakage 1
Urinary leakage from bladder 1
Intestinal obstruction 1
Wound evisceration 1
Grade IV
Postoperative bleeding 1 (1.5)
Grade V 0 (0.0)
Long-term postoperative complications
(> postoperative 30 days)
7 (10.6)
Grade I 
Grade II 
Grade IIIa 
Grade IIIb 5 (7.6)
Intestinal obstruction 3
Perforation of small bowel 1
Ureteral stricture 1
Grade IV
Septic shock 1 (1.5)
Grade V
Sepsis 1 (1.5)
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After surgery, the average lengths of stay in the ICU and the
hospital were 1.7 days and 20.2 days, respectively. Levin tubes
inserted before the operation were removed at 4.8 postoperative
days on average. In addition, patients began to eat a soft diet at
9.5 postoperative days. Closed suction drains were removed at
13.4 days. After CRS with HIPEC, 2 patients were re-admitted to
the ICU due to sepsis and postoperative bleeding.
After CRS with HIPEC, 77.3% of the patients received
postoperative chemotherapy. Among them, 39 patients (59.1%)
were treated with adjuvant chemotherapy within the ﬁrst 2
months. Targeted chemotherapeutic agents, such as bevacizumab
or cetuximab, were used in 60.6% of the patients, and FOLFIRI
with bevacizumab was used most commonly as the ﬁrst line
adjuvant chemotherapy after HIPEC. Re-admission related to
postoperative complications occurred in 9.1% of the patients
(Table 3).3.4. Postoperative complications according to the clavien-
dindo classiﬁcation
The overall rate of short-term complications was 74.2%,whereas
the rate of long-term complications was 10.6%. Among short-
term complications, 62.1% were grade I-II complications, and
12.1% were grade III-V complications. Long-term complications
consisted of grade III-V complications: grade III, 7.6%; grade IV,
1.5%; and grade V, 1.5%.
Among short-term complications, hematologic abnormalities
were the most common grade II complications: neutropenia
(15.2%) and thrombocytopenia (6.1%). In addition, 7.6% of the
patients required transfusions postoperatively. Among patients
with grade IIIa complications, 3 received interventional therapies
for pleural effusion, ureteral stricture, and postoperative4bleeding. In addition, there were 4 patients who underwent a
re-operation due to postoperative leak, intestinal obstruction,
and wound evisceration as grade IIIb complications.
Among long-term complications, grade III complications were
recorded in 5 patients (7.6%). In addition, 1 patient with a grade
IV long-term complication suffered from septic shock, which
developed from bile leakage after hepatectomy following CRS
with HIPEC. The main cause of grade V complications was
sepsis, which postoperatively occurred with pneumonia. Detailed
descriptions are shown in Table 4, and the proportions of
postoperative complications according to the follow-up period
are demonstrated in Fig. 1.
4. Discussion
CRS and HIPEC have been applied to treat patients with
peritoneal carcinomatosis originating from appendiceal cancer,
colorectal cancer, ovarian cancer, and pseudomyxoma peritonei.
Figure 1. Postoperative complications according to Clavien–Dindo classiﬁca-
tion.
Figure 2. Completeness of cytoreduction (CC) score according to the
peritoneal cancer index (PCI). PCI = peritoneal cancer index.
Park et al. Medicine (2017) 96:21 www.md-journal.comAccording to the tumor cell entrapment hypothesis, intraoper-
ative manipulation of the primary cancer and cancer-contami-
nated ﬂuid can result in local-regional dissemination of tumor
cells. In addition, spillage of free cancer cells in the abdominal
cavity can be implanted in the peritoneal surface and progress to
peritoneal metastasis.[19] In addressing these issues, HIPEC has
advantages of eradicating residual tumor cells in the peritoneal
space, allowing anticancer agents to penetrate into the tumor core
and increase cytotoxic effects. Since Sugarbaker et al ﬁrst began a
prospective randomized trial for peritoneal surface malignancy in
1985, CRS with HIPEC has been regarded as an effective
treatment to prolong survival in patients with colorectal cancer
with peritoneal carcinomatosis.[5,6,20,21]
The perioperative results in this study were comparable to
those in previous reports for CRS with HIPEC. The mean
operation time was 9.4hours (range 3.4–19.6), and the length of
hospital stay was 20.2 days (8–70). In addition, 59.1% of the
patients began postoperative chemotherapy within 2 postopera-
tive months. According to Kusamura et al,[10] 420 patients who
underwent CRS with HIPEC showed a mean operation time of
563 minutes and a hospital stay of 22 days. In addition, Polanco
et al[22] reported that the median operation time was 430 minutes
and the length of hospital stay was 15.86 days in an analysis of
370 cases. Although the days to begin the ﬁrst soft diet and
removal of inserted drains were delayed more than 4 to 5 days,
compared with conventional colorectal surgeries, the postopera-
tive outcomes of this study were acceptable in terms of the
extensive surgical procedures of CRS, as well as HIPEC.[23,24]
HIPEC seeks to increase cytotoxic effects in tumor cells and to
reduce systemic toxicities.[25] To satisfy these purposes, it is
crucial to select proper anticancer drugs directed for HIPEC. In
this study, we used 35mg/m2 of mitomycin-C mixed in 3L of
1.5% dextrose peritoneal dialysis solution, which was a similar
protocol of Verwaal et al.[5,6] However, mitomycin-C has adverse
effects of myelosuppression and renal toxicity. Predisposing
factors that decrease excretion of mitomycin-C from the kidney
and increase plasma concentration of mitomycin-C might affect
postoperative myelosuppression after HIPEC. In addition,
immunologic suppression from postoperative surgical stress
might aggravate its negative impact on postoperative recovery in
hematopoietic systems.[26] Thus, it is important to conduct
proper patient selection and to consider dose reductions of
anticancer agents for HIPEC in patients who have a very low5BMI, long period of prior chemotherapies, decreased renal
function, and are older than 60 years old.
Postoperative complications occurred in 74.2% of the patients
in the short-term period and in 10.6% in the long-term period. In
the short-term period, grade I-II complications developed in
62.1% of the patients. The most common complications of grade
II were hematologic abnormalities: neutropenia (15.2%) and
thrombocytopenia (6.1%). These developed within 5–7 postop-
erative days and were treated using hematopoietic agents. In
previous studies, the rates of postoperative major complications
after CRS with HIPEC were approximately 30–40%.[8,27]
However, the rate of postoperative major complications in this
study was 12.1% in the short-term period and 10.6% in the long-
term period. Although CRS and HIPEC were performed in just
66 cases as an early experience, our results for postoperative
complications are acceptable, compared to previous reports. On
the other hand, while the majority of short-term complications
were grades I-II, all long-term complications were grades III-V as
shown in Fig. 1. This suggests that long-term complications
require more attention, because they can result in more severe
morbidities, compared to short-term complications. It is known
that CRS with HIPEC requires a steep learning curve (100–140
cases) to ensure proﬁcient performance of the techniques.[10,27]
Because of the aggressive and high-skilled procedures of CRS
with HIPEC, postoperative morbidities have been found to differ
among institutions, from 10% to 60%.[28] However, it is
remarkable that the rate of perioperative mortality is nearly zero
at high-volume centers with greater experience with CRS with
HIPEC.[28] In these aspects, intensive training and sustained
efforts to accumulate surgical experience are key to achieving
successful postoperative outcomes after CRS with HIPEC.[29]
Both PCI and CC scores are regarded as key prognostic factors
that affect the clinical and oncologic outcomes after CRS with
HIPEC.[3,7,30] Because PCI assesses tumor distribution quantita-
tively, it can predict the likelihood of complete cytoreduction.[30]
As shown in Fig. 2, patients with low PCI had high rates of CC-0.
On the other hand, patients with high PCI had low rates of CC-0
and high rates of CC-2. These correlations suggest that extensive
peritoneal seeding can result in incomplete resections and a poor
prognosis.[25] In this study, CC-2 occurred in 22.7% of the
patients. Although preoperative imaging studies were performed
to examine the extent of peritoneal carcinomatosis before CRS
with HIPEC, intraoperative PCI was usually higher than
preoperatively predicted values, because it is still difﬁcult to ﬁnd
chemotherapy in peritoneal surface malignancies. Ann Surg 2012;255:
Park et al. Medicine (2017) 96:21 Medicinesmall peritoneal seeding nodules in the current CT scans.
Preoperatively, improved diagnosis of the extent of peritoneal
seeding is necessary to determine a patient’s eligibility for CRS
with HIPEC and to enhance both postoperative and oncologic
outcomes.
This study has limitations of using a small study population to
assess short-term outcomes after CRS plus HIPEC. Although our
prospective data collection offers advantages of recording
detailed postoperative outcomes, assessment with larger numbers
of patients is needed to conﬁrm our clinical outcomes after CRS
with HIPEC. However, this study is still meaningful as we
demonstrated acceptable short-term clinical outcomes of CRS
with HIPEC, which can be used as effective treatment strategies
to treat peritoneal metastasis from colorectal cancer.
In conclusion, CRS with HIPEC was deemed feasible for
treating appendiceal and colorectal cancer with peritoneal
metastasis. We expect that this method will be more widely
accepted in treating peritoneal carcinomatosis in patients with
stage IV appendiceal and colorectal cancer.Acknowledgments
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